Trisomy 7 by Dual-Color Fluorescence in Situ Hybridization: A Potential Biological Marker for Prostate Cancer Progression

Clinical Cancer Research

Volumn 2, Issue 9, 1996, Pages 1553-1558

  Wang, Rui Yu ^a   Troncoso, Patricia ^a   Palmer, Judy L ^a   El Naggar, Adel K ^a   Liang, Jan C ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DNA;

ARTICLE; CHROMOSOME 7; DISEASE COURSE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; HUMAN; MALE; PATHOLOGY; PLOIDY; PROSTATE TUMOR; TRISOMY;

BIOLOGICAL MARKERS; CHROMOSOMES, HUMAN, PAIR 7; DISEASE PROGRESSION; DNA, NEOPLASM; FLOW CYTOMETRY; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; PLOIDIES; PROSTATIC NEOPLASMS; TRISOMY;

EID: 0030223002     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Atkin, N. B., and Baker, M. C. Chromosome 10 deletion in carcinoma of the prostate. N. Engl. J. Med., 312: 315, 1985.
2. Brothman, A. R., Peehl, D. M., Patel, A. M., and McNeal, J. E. Frequency and pattern of karyotypic abnormlaities in human prostate cancer. Cancer Res., 50: 3795-3803, 1990.
3. Micale, M. A., Mohamed, A., Sakr, W., Powell, I. J., and Wolman, S. R. Cytogenetics of primary prostatic adenocarcinoma. Clonality and chromosome instability. Cancer Genet. Cytogenet., 61: 165-173, 1992.
4. Lundgren, R., Mandahl, N., Heim, S., Limon, J., Henrikson, H., and Mitelman, F. Cytogenetic analysis of 57 primary prostatic adenocarcinomas. Genes Chromosomes & Cancer, 4: 16-24, 1992.
5. Brothman, A. R., Patel, A. M., Peehl, D. M., and Schellhammer, P. F. Analysis of prostatic tumor cultures using fluorescence in situ hybridization (FISH). Cancer Genet. Cytogenet., 62: 180-185, 1992.
6. Micale, M. A., Sanford, J. S., Powell, I. J., Sakr, W. A., and Wolman, S. R. Defining the extent and nature of cytogenetic events in prostatic adenocarcinoma: paraffin FISH vs. metaphase analysis. Cancer Genet. Cytogenet., 69: 7-12, 1993.
7. Macoska, J. A., Micale, M., Benson, P., Sakr, W., and Wolman, S. R. Extensive genetic alterations in prostate cancer revealed by dual PCR and FISH analysis. Genes Chromosomes & Cancer, 8: 88-97, 1993.
8. Konig, J. J., Teubel, W., van Dongen, J. W., Romijn, J. C., Hagemeijer, A., and Schroder, F. H. Loss and gain of chromosomes 1, 18, and Y in prostate cancer. Prostate, 25: 281-291, 1994.
9. Jones, E., Zhu, X. L., Rohr, L. R., Stephenson, R. A., and Brothman, A. R. Aneusomy of chromosomes 7 and 17 detected by FISH in prostate cancer and the effects of selection in vitro. Genes Chromosomes & Cancer, 11: 163-170, 1994.
10. Baretton, G. B., Valina, C., Vogt, T., Schneiderbanger, K., Diebold, J., and Lohrs, U. Interphase cytogenetic analysis of prostatic carcinomas by use of nonisotopic in situ hybridization. Cancer Res., 54: 4472-4480, 1994.
11. Visakorpi, T., Hyytinen, E., Kallioniemi, A., Isola, J., and Kallioniemi, O-P. Sensitive detection of chromosome copy number aberrations in prostate cancer by fluorescence in situ hybridization Am. J. Pathol., 145: 624-630, 1994.
12. Brown, J. A., Alcaraz, A., Takahashi, S., Persons, D. L., Lieber, M. M., and Jenkins, R. B. Chromosomal aneusomies detected by fluorescent in situ hybridization analysis in clinically localized prostate carcinoma. J. Urol., 152: 1157-1162, 1994.
13. Takahashi, S., Qian, J., Brown, J. A., Alcaraz, A., Bostwick, D. G., Lieber, M. M., and Jenkins, R. B. Potential markers of prostate cancer aggressiveness detected by fluorescence in situ hybridization in needle biopsies. Cancer Res., 54: 3574-3579, 1994.
14. Zitzelsberger, H., Szucs, S., Weier, H-U., Lehmann, L., Braselmann, H., Enders, S., Schilling, A., Breul, J., Hofler, H., and Bauchinger, M. Numerical abnormalities of chromosome 7 in human prostate cancer detected by fluorescence in situ hybridization (FISH) in paraffin-embedded tissue sections with centromere-specific DNA probes. J. Pathol., 172: 325-335, 1994.
15. Alcaraz, A., Takahashi, S., Brown, J. A., Herath, J. F., Bergstralh, E. J., Larson-Keller, J. J., Lieber, M. M., and Jenkins, R. B. Aneuploidy and aneusomy of chromosome 7 detected by fluorescence in situ hybridization are markers of poor prognosis in prostate cancer. Cancer Res., 54: 3998-4002, 1994.
16. Visakorpi, T., Kallioniemi, A. H., Syvanen, A-C., Hyytinen, E. R., Karhu, R., Tammela, T., Isola, J. J., and Kallioniemi, O-P. Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res., 55. 342-347, 1995.
17. Babu, V. R., Miles, B. J., Cerny, J. C., Weiss, L., and Van Dyke, D. L. Cytogenetic study of four cancers of the prostate. Cancer Genet. Cytogenet., 48: 83-87, 1990.
18. Zenklusen, J. C., Thompson, J. C., Tronsoco, P., Kagan, J., and Conti, C. J. Loss of heterozygosity in human primary prostate carcinomas: a possible tumor suppressor gene at 7q31.1. Cancer Res., 54: 6370-6373, 1994.
19. Bergerheim, U. S. R., Kumini, K., Collins, V. P., and Ekman, P. Deletion mapping of chromosomes 8, 10, and 16 in human prostate carcinoma. Genes Chromosomes & Cancer, 3: 215-220, 1991.
20. Kagan, J., Stein, J., Babaian, R. J., Joe, Y-S., Pisters, L. L., Glassman, A. B., von Eschenbach, A. C., and Troncoso, P. Homozygous deletions at 8p22 and 8p21 in prostate cancer implicate these regions as the sites for candidate tumor suppressor genes. Oncogene, 11: 2121-2126, 1995.
21. Carter, B. S., Ewing, C. M., Ward, W. S., Treiger, B. F., Aalders, T. W., Schalken, J. A., Epstein, J. I., and Isaacs, W. B Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc. Natl. Acad. Sci. USA, 87: 8751-8755, 1990.
22. Bookstein, R., Rio, P., Madreperla, S., Hong, F., Allred, C., Grizzle, W. E., and Lee, W-H. Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma Proc. Natl. Acad Sci. USA, 87: 7762-7766, 1990.
23. Bookstein, R., MacGrogan, D., Hilsenbeck, S. G., Sharkey, F., and Allred, D. C. p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res., 53: 3369-3373, 1993.
24. Gao, X., Zacharek, A., Salkowski, A., Grignon, D. J., Sakr, W., Porter, A. T., and Honn, K. V. Loss of heterozygosity of the BRCA1 and other loci on chromosome 17q in human prostate cancer. Cancer Res., 55: 1002-1005, 1995.
25. Brewster, S. F., Browne, S., and Brown K. W. Somatic allelic loss at the DCC, APC, nm23-H1, and p53 tumor suppressor gene loci in human prostatic carcinoma. J. Urol., 151: 1073-1077, 1994.
26. Isaacs, W. B., Bova, S., Morton, R. A., Bussemakers, M. J. G., Brooks, J. D., and Ewing, G. M. Molecular genetics and chromosomal alterations in prostate cancer. Cancer (Phila.), 75: 2004-2012, 1995.
27. Forsslund, G., Esposti, P-L., Nilsson, B., and Zetterberg, A. The prognostic significance of nuclear DNA content in prostatic carcinoma. Cancer (Phila.), 69: 1432-1438, 1992.
28. Whitmore, W. F., Jr. Natural history of low-stage prostatic cancer and the impact of early detection. Urol. Clin. North Am., 17: 689-697, 1990.
29. Bandyk, M. G., Zhao, L., Troncoso, P., Pisters, L. L., Palmer, J. L., von Eschenbach, A. C., Chung, L. W. K., and Liang, J. C. Trisomy 7: a potential cytogenetic marker of human prostate cancer progression. Genes Chromosomes & Cancer, 9: 19-27, 1994.
30. Zajicek, J. Aspiration Biopsy Cytology (Part 2). Monographs in Clinical Cytology, Vol. 7. Basel, Switzerland: S. Karger A G., 1979.
31. Traganos, F., Darzynkiewicz, Z., Sharpless, T., and Melamed, M. R. Simultaneous staining of ribonucleic acids in unfixed cells using acridine orange in a flow cytofluorometric system. J. Histochem. Cytochem., 25: 46-56, 1977.
32. Hiddeman, W., Schumann, J., Andreeff, M., Barlogie, B., Herman, C. J., Mayall, B. H., Murphy, R. F., and Sandberg, A. A. Convention on nomenclature for DNA cytometry. Cytometry, 5: 445-446, 1984.
33. Conover, W. J. Practical Nonparametric Statistics. New York: John Wiley & Sons, Inc , 1980.
34. Bartlett, J. M., Langdon, S. P., Simpson, B. J., Stewart, M., Katsaros, D., Sismondi, P., Love, S., Scott, W. N., Williams, A. R., Lessells, A. M., Macleod, K. G., Smyth, J. F., and Miller, W. R. The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br. J. Cancer, 73: 301-306, 1996.
35. Gasparini, G., Bevilacqua, P., Pozza, F., Meli, S., Boracchi, P., Marubini, E., and Sainsbury, J. R. Value of epidermal growth factor receptor status compared with growth fraction and other factors for prognosis in early breast cancer. Br. J. Cancer, 66: 970-976, 1992.
36. Hirono, Y., Tsugawa, K., Fushida, S., Ninomiya, I., Yonemura, Y., Miyazaki, I., Endou, Y., Tanaka, M., and Sasaki, Y. Amplification of epidermal growth factor receptor gene and its relationship to survival in human gastric cancer. Oncology, 52: 182-188, 1995.
37. Takahashi, S., Shan, A. L., Ritland, S. R., Delacey, K. A., Bostwick, D. G., Lieber, M. M., Thibodeau, S. N., and Jenkins, R. B. Frequent loss of heterozygosity at 7q31.1 in primary prostate cancer is associated with tumor aggressiveness and progression. Cancer Res., 55: 4114-4119, 1995.
38. Collard, J. G., van de Poll, M., Scheffer, A., Roos, E., Hopman, A. H. M., van Kessel, H. M. G., and van Dongen, J. J. M. Location of genes involved in invasion and metastasis on human chromosome 7. Cancer Res., 47: 6666-6670, 1987.